Excaliard

Isis Pharmaceuticals last month responded to objections about its use of a former executive as an expert in its patent-infringement lawsuit against Santaris Pharma, arguing to the court that a purported conflict of interest does not exist and an order allowing the expert access t

This article has been updated to clarify details regarding Traversa Therapeutics' bankruptcy proceedings.

RXi Pharmaceuticals has completed patient dosing in the second of two phase I trials of its lead drug candidate, the anti-scarring agent RXI-109, and is on track to initiating a phase II study before the end of the year, the company's top executive said last week.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.